Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2004-12-03
2010-06-15
Moore, Susanna (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C544S120000, C544S357000, C544S405000, C514S252110, C514S255050
Reexamination Certificate
active
07737143
ABSTRACT:
A compound of general formula (I) or pharmaceutically acceptable prodrugs, salts, hydrates, solvates, crystal forms or diastereomers thereof is described. A method of treating kinase-associated disease states using the compound of formula (I) is also described.
REFERENCES:
patent: 6498165 (2002-12-01), Armstrong et al.
patent: WO-00/62778 (2000-10-01), None
patent: WO-03/099811 (2003-12-01), None
Vippagunta et al, “Crystalline Solids” Advanced Drug Delivery Reviews, vol. 48, pp. 3-26 (2001).
Gavezzotti, “Are Crystal Structures Predictable?” Accounts of Chemical Research, vol. 27, pp. 309-314 (1994).
Duhé et al, “Negative Regulation of Janus Kinases” Cell Biochemistry and Biophysics, vol. 34(1), pp. 17-59 (2001).
Al-Dabbagh and Smith, “Species differences in oxidative drug metabolism: some basic considerations.” Archives of toxicology. Supplement. Archiv fur Toxikologie. supplement, vol. 7, pp. 219-231 (1984).
Hans Bundgaard, Design of Prodrugs, p. 1. © 1985 Elsevier Science Publishers.
Richard B. Silverman, The Organic Chemistry of Drug Design and Drug Action, pp. 352-400. © 1992 Academic Press, Inc.
International Search Report for PCT/AU2004/001690, mailed on Jan. 20, 2005, 2 pages.
Kozma et al., EMBO J. (1988) 7:147-154.
Sadowski et al., Mol. Cell. Biol. (1986) 6:4396-4408.
Spiotto and Chung, Prostate (2000) 42:88-98.
Wilks and Kurban, Oncogene (1988) 3:289-294.
Wilks et al., Mol. Cell. Biol. (1991) 11:2057-2065.
Bu Xianyong
Burns Christopher John
Wilks Andrew Frederick
Moore Susanna
Morrison & Foerster / LLP
YM Biosciences Australia Pty Ltd
LandOfFree
Substituted pyrazines as kinase inhibitors does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Substituted pyrazines as kinase inhibitors, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Substituted pyrazines as kinase inhibitors will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4245052